Terunaga Nakagawa, M.D., Ph.D.
- Professor of Molecular Physiology and Biophysics
Terunaga Nakagawa, M.D., Ph.D.
- Professor of Molecular Physiology and Biophysics
terunaga.nakagawa@Vanderbilt.Edu
766 Robinson Research Building
Research Program
Research Description
Jennifer Below, Ph.D.
- Professor of Medicine
- Director, Vanderbilt Genetics Institute (VGI)
Jennifer Below, Ph.D.
- Professor of Medicine
- Director, Vanderbilt Genetics Institute (VGI)
jennifer.e.below@vanderbilt.edu
Research Program
Research Description
Eden Biltibo, M.D., M.S.C.I.
- Assistant Professor of Medicine
Eden Biltibo, M.D., M.S.C.I.
- Assistant Professor of Medicine
eden.a.biltibo@vumc.org
Research Program
Research Description
Study CDFV890G12101 is an open-label, phase 1b, multicenter study with a randomized two-dose
optimization part, and a dose expansion part consisting of two groups evaluating DFV890 in
patients with myeloid diseases. The purpose of this study is to assess the safety,
tolerability, pharmacokinetics, pharmacodynamics, efficacy and recommended dose for single
agent DFV890 in patients with lower risk (LR: very low, low or intermediate risk)
myelodysplastic syndromes (LR MDS) and lower risk chronic myelomonocytic leukemia (LR CMML).
Lauren Woodard, PhD
- Assistant Professor of Nephrology
Lauren Woodard, PhD
- Assistant Professor of Nephrology
lauren.woodard@vumc.org
Research Program
Research Description
This study is being done to find out if tucatinib with other cancer drugs works better than
standard of care to treat participants with HER2 positive colorectal cancer. This study will
also test what side effects happen when participants take this combination of drugs. A side
effect is anything a drug does to the body besides treating your disease.
Participants in this study have colorectal cancer that has spread through the body
(metastatic) and/or cannot be removed with surgery (unresectable).
Participants will be assigned randomly to the tucatinib group or standard of care group. The
tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group
will get either:
- mFOLFOX6 alone,
- mFOLFOX6 with bevacizumab, or
- mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs
given in this study are used to treat this type of cancer.
